Year: 2025

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

Written by Customer Service on June 10, 2025. Posted in Public Companies.

Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy® (semaglutide 7.2 mg) for those in need of greater weight loss Data will expand semaglutide evidence in both a clinical and real-world setting, including cardiometabolic and kidney health benefits for those with obesity and diabetes Novo Nordisk continues to pioneer obesity innovation, including presentation of full Phase 3 REDEFINE 1 and 2 trial results, providing insights into the transformational potential of CagriSemaBagsværd, Denmark, 10 June – Novo Nordisk today announced that new data from its industry-leading portfolio in metabolic and cardiovascular health will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago US, 20 – 23 June 2025. A total of 29 abstracts will be presented, including...

Academy Sports + Outdoors Reports First Quarter Fiscal 2025 Results

Written by Customer Service on June 10, 2025. Posted in Earnings Releases And Operating Results.

First Quarter Sales Decline (0.9)%; Comparable Sales Declined (3.7)% eCommerce Sales Increase 10.2%; New Stores Continue to Comp Positive Low Single Digits First Quarter Diluted GAAP EPS of $0.68; Returned $108M to Shareholders through Share Buy Backs and Dividends Opened Five New Stores in Pennsylvania, Maryland, Missouri and North Carolina Company Revises Guidance to Account For Multiple Tariff Scenarios While Maintaining High End KATY, Texas, June 10, 2025 (GLOBE NEWSWIRE) — Academy Sports and Outdoors, Inc. (Nasdaq: ASO) (“Academy” or the “Company”) today announced its financial results for the first quarter ended May 3, 2025. “During the first quarter we saw continued progress across our strategic initiatives, including the opening of five new stores, and the biggest brand launch in the Company’s...

Form 8.3 – [MARLOWE PLC – 09 06 2025] – (CGWL)

Written by Customer Service on June 10, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree MARLOWE PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Comscore and Adelaide Expand Access to High-Quality, Attention-Optimized Curated Deals across PubMatic’s platform

Written by Customer Service on June 10, 2025. Posted in Public Companies.

New collaboration combines Comscore’s trusted inventory rankings with Adelaide’s attention metrics, enabling advertisers to drive higher engagement and maximize campaign impact RESTON, Va., June 10, 2025 (GLOBE NEWSWIRE) — Comscore (NASDAQ: SCOR), a global leader in measuring and analyzing consumer behaviors, today announced the expansion of its Comscore-Certified Deal IDs to include Adelaide’s attention-based metric in PubMatic’s premium sell-side supply including many of the top CTV publishers. Adelaide is a leader in attention-based media measurement and PubMatic is a leading technology platform that enables publishers to manage and monetize their digital advertising inventory programmatically. This collaboration enables media buyers to reach top-quality inventory certified by Comscore, with placements strategically optimized...

Form 8.3 – [GLOBALDATA PLC – 09 06 2025] – (CGWL)

Written by Customer Service on June 10, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree GLOBALDATA PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Form 8.3 – [CRANEWARE PLC – 09 06 2025] – (CGWL)

Written by Customer Service on June 10, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree CRANEWARE PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Form 8.3 – [ALPHA GROUP INTERNATIONAL PLC – 09 06 2025] – (CGAML)

Written by Customer Service on June 10, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ALPHA GROUP INTERNATIONAL PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Written by Customer Service on June 10, 2025. Posted in Public Companies.

ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the United Kingdom (UK) and has an initial 10 years of market exclusivity from the date of initial marketing authorization from the Medicines and Healthcare products Regulatory Agency. “Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with...

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

Written by Customer Service on June 10, 2025. Posted in Public Companies.

CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced presentations at the American Diabetes Association’s (ADA) 85th Scientific Sessions, taking place June 20-23. 2025, Chicago, IL.846-P – Safety, Pharmacokinetics, and Pharmacodynamics of MBX 1416, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers: A Phase 1 Randomized TrialPresenter: Elisa Fabbrini, MD. PhD. Session: General Poster SessionDate: Sunday June 22nd, 2025 Time 12:30-1:30pm CT 845-P – MBX 1416, a Selective GLP-1 Antagonist, Elevates and Sustains Blood Glucose in Rats without Change in Body WeightPresenter: Richard...

Provident Bank Expands Newark Presence with New Branch, Reinforces Commitment to Local Community

Written by Customer Service on June 10, 2025. Posted in Public Companies.

New location marks Provident’s fourth branch in Newark and continued commitment to the cityGreater Life Check PresentationLeft to Right: Maria Westbrook, Co-Founder/VP of Administration & Finance, Greater Life; Chanel Mainor, Fund Development, Greater Life; Israel Morales, VP, Banking Center Manager, Provident Bank; Chris Martin, Executive Chairman, Provident BankSt. Johns Soup Kitchen PhotoLeft to Right: Jorge Fernandes, FVP, Market Sales Manager, Provident Bank; Barbara Cury, Executive Director of Social Services, St. Johns Soup Kitchen; Israel Morales, VP, Banking Center Manager, Provident Bank; Chris Martin, Executive Chairman, Provident BankRibbon Cutting PhotoLeft to Right: Michael J. Silva, Councilman, East Ward, City of Newark; Jacqueline Quiles, Deputy Mayor, City of Newark; Jim Kirkos, President...

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals